Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04594798 · ClinicalTrials.gov registry record · Phase 2
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
A Phase 2 study of Lymphoma, B-Cell and DLBCL, sponsored by University of Rochester.
- Active
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT04594798: Active Phase 2 study of Lymphoma, B-Cell and DLBCL, sponsored by University of Rochester.
NCT04594798 is a Phase 2 study of Lymphoma, B-Cell and DLBCL that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 39 participants, below the 200-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04594798, a Phase 2 study of Lymphoma, B-Cell and DLBCL, is active but no longer recruiting, sponsored by University of Rochester.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
Primary Outcome
Measure of time from study enrollment until progression.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Prednisone
- DRUG Polatuzumab vedotin
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
What the registry record for NCT04594798 still lists
NCT04594798 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 200-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Lymphoma, B-Cell appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04594798 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04594798 about?
NCT04594798 is a clinical study titled "A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL". The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
What is the current status of trial NCT04594798?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2021-09-20. Estimated completion is 2026-07-31.
What conditions does trial NCT04594798 study?
This clinical trial studies the following conditions: Lymphoma, B-Cell, DLBCL.
What interventions are being tested in trial NCT04594798?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Prednisone (DRUG), Polatuzumab vedotin (DRUG).
Who is sponsoring clinical trial NCT04594798?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04594798 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, B-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04594798's enrollment target sits among peer trials
39 22nd of 31 higher than 9 of 31 other Lymphoma, B-Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, B-Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
RECRUITING · Phase 2
-
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
COMPLETED · Phase 2
-
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
COMPLETED · Phase 2
-
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
COMPLETED · Phase 2
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI